Navigation Links
QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues

Project to Utilize World-Class Software & Database Developed in West

Michigan to Help Advance Disease Diagnosis and Treatment Options

VENLO, Netherlands and GRAND RAPIDS, Mich., Feb. 14 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced the formation of a collaborative effort with its affiliates and QIAGEN NV (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) to support research focused on discovering molecular biomarkers capable of helping diagnose breast cancer and other women's health issues. Financial terms of the agreement were not disclosed.

At the center of the collaboration is the CMM's access to clinical samples, its molecular analysis capabilities as well as XenoBase, a one-of-a- kind software and database system developed at the Van Andel Research Institute. This specialized bio-informatic system is capable of analyzing a wide range of molecular and conventional clinical data to help researchers identify clinically actionable associations between diseases, biomarkers and treatments. XenoBase is the result of more than five years of work by Craig Webb, Ph.D. and Jeremy Miller, Ph.D., of the Van Andel Research Institute, a co-founding joint venture partner of CMM. Based on the result of QIAGEN's initial research, the CMM may also provide laboratory-based genomics and proteomics services to assist QIAGEN in the development and validation of new molecular diagnostic tests.

QIAGEN is a leading global provider of genetic sample and assay technologies, with 30 locations and more than 2,600 employees worldwide and a sales runrate of more than $800 million in 2008. Grand Rapids, Mich.-based CMM ( is a CLIA-certified, CAP-accredited, state-of-the-art clinical diagnostics laboratory, founded early in 2007. The CMM's unique capabilities, including XenoBase access, on-site microarray-based DNA typing and gene expression profiling, played a vital role in bringing QIAGEN to West Michigan, as did the capabilities of CMM joint venture partners the Van Andel Institute and Spectrum Health.

"CMM is pleased that QIAGEN, a global leader in molecular diagnostics recognizes the value of software-driven biomarker research and how advanced the resources in West Michigan truly are in this rapidly emerging field," said Daniel H. Farkas, PhD, Executive Director of CMM. "The speed and analytical depth of XenoBase coupled with the CMM's access to clinical samples can give QIAGEN a competitive advantage in the development of new molecular diagnostic tests, especially in the field of oncology. The CMM is pleased to be the focal point for a West Michigan/QIAGEN partnership and is ready to support the genomic- and proteomic-based laboratory work that will surely follow."

We are impressed by the capabilities that CMM has assembled and the commitment of CMM and its supporters. We look forward to working with this prestigious center to develop next-generation molecular markers for our long- term pipeline," said Dr. Joachim Schorr, Senior VP of Global Research and Development, QIAGEN.

"We are delighted to enter into an agreement with QIAGEN to demonstrate the efficiency of the XenoBase technology in creating predictive algorithms for molecular diagnostic applications," said Craig Webb, PhD, Director of the Program of Translational Medicine at the Van Andel Institute. "The relationship between CMM and QIAGEN hopefully represents the beginnings of a molecular diagnostic pipeline that can establish an accelerated means to introduce biomarkers into medical practice."


QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN is using the term molecular diagnostics. Further information about QIAGEN can be found at

About CMM:

The Center for Molecular Medicine, a joint venture between Grand Rapids, Mich.-based Spectrum Health and Van Andel Institute (VAI), brings West Michigan a cutting-edge laboratory that will aid in early diagnoses and enhance personalized medicine. It offers 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness and other conditions at the DNA, RNA and protein levels. The Center brings new and increased opportunities for diagnostics and pharmaceutical companies to conduct trials in a world-class medical and clinical research environment. For more information, visit

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

SOURCE Center for Molecular Medicine
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
6. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
7. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
Post Your Comments:
(Date:11/30/2015)... 2015  Precision Image Analysis Inc. (PIA), a ... announce a dramatic expansion of its capabilities as ... its ISO-9001:2008 certification for its Quality Management System, ... protocols and procedures. This expansion enables PIA to ... Core Lab services include design and optimization of ...
(Date:11/30/2015)... November 30, 2015 Mexico Healthcare and Life ... Sciences Report 2015 . --> Pharmaboardroom releases its new ... Latin America , a country of over 122 ... country of over 122 million people. --> It offers ... or life sciences insights into the second largest pharma and healthcare ...
(Date:11/30/2015)... 30, 2015 Elbit Imaging Ltd. ... announced today that it was informed by InSightec Ltd. ("InSightec"), ... (MFDS) has approved its Exablate Neuro system to treat ... --> Insightec,s Exablate Neuro platform is ... combines two technologies: Focused Ultrasound, which is used to ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published 32nd ... System (NPDS) reveals that in 2014, someone called a poison center about every ... of which were human exposure cases. , The American Association of Poison Control ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., ... womb. "My last baby had high blood pressure due to loud noises," she said, ... their babies from noise pollution as well as radio waves and microwaves." , The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
Breaking Medicine News(10 mins):